News
Pioneer in Regenerative Medicine Presents Keynote Address at Orthopaedic Surgeons Biologics Symposium
CEO of Personalized Stem Cells and VetStem delivered a talk on real word evidence at the American Academy of Orthopaedic Surgeons Biologics Symposium.
Personalized Stem Cells Announces New Chief Development Officer
Regenerative medicine company, Personalized Stem Cells, Inc., announces a new Chief Development Officer, Dr. Anne S. Hale.
Personalized Stem Cells Announces Brazilian Clearance of Long-Haul COVID Study Licensed to Sorrento Therapeutics
Personalized Stem Cells, Inc (PSC), an adipose-derived stem cell company, announces the Brazilian Health Regulatory Agency (Anvisa) authorized a Phase 2 stem cell clinical trial for patients suffering with persistent pulmonary compromise as a result of COVID-19 (aka...
Personalized Stem Cells CEO Presents Clinical Trial Results at Annual IFATS Meeting
CEO and founder of Personalized Stem Cells, Inc (PSC), Dr. Robert Harman, recently presented clinical trial results at the annual International Federation for Adipose Therapeutics and Science (IFATS) meeting in Ft. Lauderdale, FL. PSC, an adipose derived stem cell...
Personalized Stem Cells Announces First Patient in Brazilian COVID-19 Clinical Trial Licensed to Sorrento Therapeutics
Personalized Stem Cells announces first patient enrolled in Phase 2 Brazilian COVID-19 stem cell clinical trial licensed to Sorrento Therapeutics.
Personalized Stem Cells Announces Brazilian Approval for COVID-19 Clinical Trial Licensed to Sorrento Therapeutics
Personalized Stem Cells announces Brazilian authorization for Phase 2 COVID-19 stem cell clinical trial licensed to Sorrento Therapeutics.
Personalized Stem Cells Announces Enrollment Complete for COVID-19 Clinical Trial Licensed to Sorrento Therapeutics
Personalized Stem Cells announces enrollment is complete for COVID-19 FDA approved stem cell clinical trial licensed to Sorrento Therapeutics.
Personalized Stem Cells Announces Additional Treatments in COVID-19 Clinical Trial Licensed to Sorrento Therapeutics
Personalized Stem Cells, Inc. announces additional positive results in COVID-19 FDA approved stem cell clinical trial licensed to Sorrento Therapeutics.
Personalized Stem Cells Announces Stem Cell Knee Arthritis FDA-Approved Phase 1/2a Clinical Trial Results
Personalized Stem Cells, Inc (PSC), a clinical stage biopharma cell therapy company, announces the results of its single knee osteoarthritis phase 1/2a clinical trial. The final study report has been submitted to the FDA for review and in support of a full-scale...
Personalized Stem Cells Announces First Patients Treated in COVID-19 Clinical Trial Licensed to Sorrento Therapeutics
Personalized Stem Cells, Inc (PSC), a human adipose-derived stem cell company, announces that the first patients have received stem cell therapy for the treatment of COVID-19 as part of an FDA approved clinical trial. The ongoing clinical trial and stem cell platform,...